We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MOBILion Systems Appoints Jenn Buechel to its Board of Directors

MOBILion Systems Appoints Jenn Buechel to its Board of Directors content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

MOBILion System Inc. (Chadds Ford, PA), has announced that it has appointed Jenn Buechel to serve on its Board of Directors, effective immediately.

Ms. Buechel, currently the Chief Operating Officer of Delfi Diagnostics, brings decades of life science experience developing and commercializing novel healthcare technologies from concept to market. Her proven success spans a spectrum of life science companies, including GRAIL and Guardant Health where she developed and executed successful product launch strategies, and at Genentech where she led innovative autoimmune disease treatments through Phase I and II clinical trials with external collaborators. Ms. Buechel has also held leadership roles at Amyris Biotechnology and McKinsey, and earned both a MSc Eng. in Systems Engineering and MBA from Stanford University. She is a Fellow of the Aspen Institute’s Health Innovators Fellowship and a member of the Aspen Global Leadership Network, in addition to being a member of the World Economic Forum’s Lung Cancer Collaboration.

“We are delighted to add Ms. Buechel to our Board of Directors. Her very relevant experience in bringing new diagnostic technologies to market and establishing strategic partnerships within the pharma industry is an asset to MOBILion,” said Heiner Dreismann, Chairman of MOBILion’s Board of Directors. “MOBILion is developing a highly tunable, customizable platform technology that is relevant across multiple markets, including diagnostics. As we explore these new market opportunities, Ms. Buechel will provide valuable input to product development and go to market strategy leveraging her breadth of experience in the medical diagnostics and biotherapeutics space.”

“I am excited for this opportunity to join the MOBILion Board of Directors” said Ms. Buechel. “MOBILion’s SLIM platform technology is truly unique, and I look forward to working with the team to support the development of their product roadmap, and ultimately launching impactful products within the biopharma, biomarker discovery, and clinical diagnostics markets.”

“This is a great step forward for MOBILion as we evolve from being solely focused on the development of our first product, MOBIE, to a commercial organization launching products in multiple markets,” said Dr. Melissa Sherman, MOBILion’s CEO. “Our team will benefit from Ms. Buechel’s experience as we expand our product development and commercialization efforts more broadly across multiple value-creating market segments.”